Dernières nouvelles pour HOOKIPA Pharma (NASDAQ:HOOK) Stock

HOOKIPA PHARMA INC

HOOKIPA Pharma

HOOKIPA Pharma Inc is a clinical-stage biopharmaceutical company developing a class of immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform that is designed to reprogram the body's immune system. Its oncology portfolio targets oncoviral cancer antigens and next-generation antigens and includes two primary programs in development: eseba-vec (formerly HB-200) and HB-700. Eseba-vec is in clinical development for the treatment of Human Papillomavirus 16-positive (HPV16+) head and neck cancers. It also develops infectious disease therapies in partnership with other companies. Its Hepatitis B (HBV) program, HB-400, and Human Immunodeficiency Virus (HIV) program, HB-500, are being developed in partnership with Gilead.

HOOKIPA Pharma Inc

Hooker Furnishings Corporation - Common Stock

Hooker Furnishings Corp

JPMorgan analyst Bryan M. Smilek reiterated the Overweight rating on Duolingo, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>), <a href="https://www.benzinga.com/quote/DUOL/analyst-ratings" target="_blank" rel="noreferrer noopener">with a price forecast of $500.</a>
Smilek stated that he continues to see significant potential for Duolingo to deliver strong user growth over multiple years.
The analyst noted that motivations for language learning vary by geography and language. Duolingo's 2024 Language Learning Report identifies education, social connections, entertainment, travel, and career advancement as common drivers. This highlights the diversity of both the company's user base and its total addressable market.
Also Read: <a target="_blank" href="https://www.benzinga.com/analyst-ratings/price-target/25/05/45176523/duolingo-charms-wall-street-with-viral-surge-ai-power-soaring-subscriptions" rel="noreferrer noopener">Duolingo Charms Wall Street With Viral Surge, AI Power, Soaring Subscriptions</a>
In terms of penetration, Duolingo boasts 130 million monthly active users. Smilek says that represents only about 18% of global online language learners and roughly 7% of all language learners worldwide.
Looking ahead, Duolingo is well-positioned to grow its global presence by broadening its content library, improving teaching effectiveness, investing in underpenetrated regions, and enhancing both courses and the overall learner experience, the analyst writes.
With around 90% of its user growth attributed to organic channels, Smilek sees the company to continue scaling by leveraging social-first marketing, influencer partnerships, and brand collaborations, while also expanding its localized efforts through new country manager hires in international markets.
According to Smilek, the company is also seeing success in expanding monetization efforts and growing its base of paid subscribers. Additionally, improvements in teaching effectiveness—particularly in advanced English learning—are helping to expand its total addressable market.
Continued momentum across its English proficiency test, in-app purchases, and advertising revenue streams further support this outlook. 
Smilek notes that Duolingo is on track to make significant progress toward its long-term adjusted EBITDA margin target of 30–35%, aided by economies of scale and disciplined cost management.
Price Action: DUO; shares are trading lower by 0.58% to $491.42&nbsp;at last check Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/05/45229107/paul-tudor-jones-warns-ai-could-kill-50-of-humanity-without-proper-oversight-were-creating-something-thats-really-dangerous" target="_blank" rel="noreferrer noopener">Paul Tudor Jones Warns AI Could &#8216;Kill 50% Of Humanity&#8217; Without Proper Oversight: &#8216;We&#8217;re Creating Something That&#8217;s Really Dangerous&#8217;</a></li>
</ul>
Image: Shutterstock

Equities

News

Markets

Analyst Ratings

Movers

Trading Ideas

General

DUOL

Duolingo Scores High Marks From JPMorgan As Learners, Profits Multiply

Media giant The Walt Disney Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) could highlight streaming strength, box office strength and theme park growth when the company reports second-quarter financial results before the<a href="https://www.benzinga.com/earnings"> market opens Wednesday.</a>
Here are analyst estimates for the quarter, what they&#8217;re saying before the results and key items to watch.
Earnings Estimates: Analysts expect Disney to report second-quarter revenue of $23.14 billion, up from $22.08 billion in last year's second quarter, according to data <a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506">from Benzinga Pro</a>.
The company has beaten analyst estimates for three straight quarters and five of the last 10 quarters.
Analysts expect Disney to report second-quarter earnings per share of $1.20, down from $1.21 in last year's second quarter.
What Analysts Are Saying: In a March investor note, Goldman Sachs analyst Michael Ng said the company's second-quarter financials will likely show strength in direct-to-consumer. He maintained a Buy rating and price target of $140 ahead of the results.
Ng said "Mufasa: The Lion King,&#8221; "Moana 2" and price increases will likely help the company's DTC segment.
He noted that domestic theme park attendance likely declined in the second quarter due to the shift of the Easter holiday and natural disasters. Ng highlighted that future theme park growth shows strength.
"We're encouraged by the growth in summer bookings despite recent softness in select travel datapoints and competition from Epic Universe.&#8221;
In a recent investor note, Bank of America analyst Jessica Reif Ehrlich also maintained a Buy rating with a $140 price target ahead of earnings.
She highlighted reacceleration for the Parks business, profitability for DTC and a strong movie slate that could help other business segments.
Ehrlich said there are concerns about macro uncertainty and Universal&#8217;s opening of the Epic Universe theme park in Florida, but Disney is facing comps that inflation and large costs for new cruise ships.
Read Also: <a href="https://www.benzinga.com/general/entertainment/25/04/44903063/star-wars-highlights-tv-new-movie-with-ryan-gosling-fortnite-collab-will-the-force-be-with-disney-stock">Star Wars Highlights TV, New Movie With Ryan Gosling, Fortnite Collab: Will The Force Be With Disney Stock?</a>
Key Items to Watch: Disney's theme park segment could get increased attention from investors and analysts ahead of the Epic Universe opening date of May 22, which has already found the <a href="https://www.benzinga.com/media/25/04/44721053/disney-cuts-prices-and-adds-perks-to-lure-families-back-to-orlando-parks">company offering discounts</a> to better compete.
While the theme park segment could see lower attendance during the year, it is a key driver of the company&#8217;s operating income, and management has guided operating income for the segment to grow 6% to 8% for the full fiscal year.
Disney+ and other streaming segments will be another key area to watch. The first quarter ended with 178 million Disney+ Core and Hulu subscriptions and 125 million Disney+ Core paid subscribers.
In recent quarters, the number of core Disney+ subscribers has fallen. Still, it is sometimes due to the end of previous packages and promotional offers with lower average revenue per user.
Movies will likely be a key topic in the earnings results and commentary. Disney released "Captain America: Brave New World" and "Snow White" in the quarter. "Snow White" <a href="https://www.benzinga.com/25/03/44465410/snow-white-disappoints-at-box-office-will-remake-hurt-disneys-marvel-magic-in-2025">was a disappointment </a>at the box office and the latest Captain America film was also lower than recent Marvel movies with domestic gross of $200.4 million and a worldwide total of $415.0 million.
The good news is Disney has five of the top-grossing movies in <a href="https://www.boxofficemojo.com/year/2025/?ref_=bo_yl_table_1">2025, </a>thanks to a slow slate from competitors and several 2024 carryovers. Here are the current top 10 films from Disney based on domestic gross in 2025:  
<ul>
<li>#2: "Captain America: Brave New World": $200.4 million</li>
<li>#4: "Mufasa: The Lion King": $126.4 million</li>
<li>#6: "Snow White": $86.1 million</li>
<li>#8: "Thunderbolts": $74.3 million</li>
<li>#10: "Moana 2": $56.4 million</li>
</ul>
Disney had three of the top four grossing movies in 2024: "Inside Out 2," "Deadpool &amp; Wolverine," and "Moana 2."
"Thunderbolts" <a href="https://www.benzinga.com/media/25/05/45199354/disney-marvels-thunderbolts-opens-to-162-million-globally">was recently released </a>and will be part of third quarter results and could be among the items highlighted by Disney for future growth, including the release of a third Marvel film for 2025 with "Fantastic Four: First Steps" in July.
Disney could also highlight the success of season 2 of "Andor" and strong viewership for the 2025 NFL Draft as items that will help the third quarter.
DIS Price Action: Disney stock trades at $92.16 Tuesday versus a 52-week trading range of $80.10 to $118.63. Disney stock is down 16.8% year-to-date in 2025 and down over 20% in the last year.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/25/05/45201601/trump-wants-movies-made-in-america-again-heres-what-tariffs-on-films-could-mean-for-disney-netflix-stock">Trump Wants &#8216;Movies Made In America Again&#8217;: Here&#8217;s What Tariffs On Films Could Mean For Disney, Netflix Stock</a></li>
</ul>
Photo: Shutterstock

Analyst Color

Entertainment

Price Target

Reiteration

Disney Q2 Earnings Preview: Streaming, Theme Parks, Box Office Key Items To Watch

<a href="https://www.bloomberg.com/news/articles/2025-05-06/nvidia-ceo-says-china-ai-market-is-on-course-to-hit-50-billion" title="https://www.bloomberg.com/news/articles/2025-05-06/nvidia-ceo-says-china-ai-market-is-on-course-to-hit-50-billion">https://www.bloomberg.com/news/articles/2025-05-06/nvidia-ceo-says-china-ai-market-is-on-course-to-hit-50-billion</a>

NVDA

'Nvidia CEO Says China AI Market Is On Course To Hit $50 Billion' - Bloomberg

Earnings reports from several key companies in Dan Loeb's Third Point portfolio hit the tape last week, offering fresh insight into holdings that, as of the fourth quarter of 2024, included major names across sectors.
Amazon.com, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>): Loeb cut the stake from 3,700,000 shares in the&nbsp;third quarter&nbsp;of 2024 to 3,450,000 million <a target="_blank" href="https://www.benzinga.com/news/large-cap/25/02/43673006/dan-loebs-amazon-stake-moves-a-look-at-his-trading-shifts" rel="noreferrer noopener">in&nbsp;the&nbsp;fourth quarter&nbsp;of 2024</a>.
<ul>
<li>On May 1, the company reported&nbsp;first-quarter&nbsp;net sales of&nbsp;$155.7 billion, beating a Street consensus estimate of&nbsp;$155.04 billion&nbsp;and EPS of&nbsp;$1.59, exceeding the street<a href="https://www.benzinga.com//node/45151230" target="_blank" rel="noreferrer noopener"> consensus estimate of&nbsp;$1.36</a>.</li>
<li>Amazon guided for&nbsp;second-quarter&nbsp;net sales of&nbsp;$159 billion&nbsp;to&nbsp;$164 billion, up&nbsp;7%&nbsp;to&nbsp;11% vs <a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">street view of&nbsp;$160.91 billion</a>.</li>
<li>Amazon said the&nbsp;guidance&nbsp;is subject to &#8220;unpredictable&#8221; items that include foreign exchange rates, changes in geopolitical conditions and &#8220;tariff and trade policies.&#8221;</li>
<li>CEO&nbsp;Andy Jassy&nbsp;predicted a potential shift in consumer behavior reminiscent of the pandemic era while asserting that the e-commerce <a href="https://www.benzinga.com/markets/25/05/45158172/andy-jassy-predicts-pandemic-like-consumer-shifts-says-amazon-is-maniacally-focused-on-keeping-prices-low" target="_blank" rel="noreferrer noopener">giant is doubling down on affordability</a>.</li>
<li>JPMorgan analyst Doug Anmuth highlighted Amazon's Q1 revenue and operating income which exceeded the high end of guidance, with no significant negative impact from macroeconomic or tariff issues. He also pointed to AWS margins that <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45172067/amazon-delivers-q1-on-the-steady-side-of-ok-as-analysts-highlight-aws-ai-demand" target="_blank" rel="noreferrer noopener">reached an all-time high</a>. </li>
<li>Rosenblatt analyst Barton Crockett labelled Amazon&#8217;s first-quarter as &#8220;on the steady side of OK,&#8221; but flagged the potential for impacts from tariffs which &#8220;could start hitting soon.&#8221; </li>
<li>RBC Captial Markets analyst Brad Erickson also highlighted the growth in AWS backlog and expects acceleration in <a href="https://www.benzinga.com/25/05/45163955/these-analysts-boost-their-forecasts-on-amazon-following-upbeat-q1-results" target="_blank" rel="noreferrer noopener">the second half of the year</a>. </li>
<li>Year to date (YTD), Amazon fell about 17.11%, vs. the ProShares Online Retail ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONLN#NYSE">ONLN</a>), which declined about 4.70%&nbsp;over the same time frame.</li>
</ul>
Meta Platforms, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>): According to the 13F filings released on Feb. 14, Loeb increased his stake in Facebook's parent company to 665,000, up from 545,000 in the third <a href="https://www.benzinga.com/news/large-cap/25/02/43796723/dan-loebs-third-point-boosts-meta-holdings-now-a-top-4-position" target="_blank" rel="noreferrer noopener">quarter of 2024, a 22% increase.</a>
<ul>
<li>Meta reported&nbsp;first-quarter&nbsp;revenue of&nbsp;$42.31 billion, beating&nbsp;analyst estimates of&nbsp;$41.39 billion and EPs of&nbsp;$6.43&nbsp;per share, easily beating analyst <a href="https://www.benzinga.com//node/45117948" target="_blank" rel="noreferrer noopener">estimates of&nbsp;$5.21&nbsp;per share</a>.</li>
<li>Meta expects&nbsp;second-quarter&nbsp;revenue of&nbsp;$42.5 billion&nbsp;to&nbsp;$45.5 billion&nbsp;versus&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a> estimates of&nbsp;$44.06 billion.</li>
<li>Goldman Sachs analyst Eric Sheridan pointed to CEO Mark Zuckerberg&#8216;s list of five AI-driven opportunities: improved advertising, more engaging user experiences, business messaging, Meta AI and AI devices – notably, Ray-Ban Meta AI glasses, which saw three times sales and more than four <a href="https://www.benzinga.com/quote/META/analyst-ratings" target="_blank" rel="noreferrer noopener">times active users year-over-year</a>. </li>
<li>BofA Securities analysts see Meta as well-positioned to thrive in a softer macro-economic environment and highlighted the company&#8217;s capex spend as &#8220;building <a href="https://www.benzinga.com/25/05/45144725/meta-analysts-highlight" target="_blank" rel="noreferrer noopener">a foundation for long-term growth.&#8221;</a> </li>
<li>Needham analyst Laura Martin questioned the company&#8217;s long-term terminal value, noting that Meta does not control its distribution or content and faces stiff competition from Apple, TikTok and YouTube. </li>
</ul>
Microsoft Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>): Loeb slashed his stake in the company&nbsp;from 870,000 shares&nbsp;in&nbsp;the third quarter of 2024&nbsp;to&nbsp;<a target="_blank" href="https://www.benzinga.com/news/large-cap/25/03/44115397/dan-loebs-third-point-slashes-microsoft-stake-analysts-blame-disappointing-azure" rel="noreferrer noopener">600,000 in the fourth quarter</a>.
<ul>
<li>The company reported&nbsp;third-quarter&nbsp;revenue of&nbsp;$70.07 billion, beating a Street consensus estimate of&nbsp;$68.43 billion and EPS of&nbsp;$3.46, beating a Street <a href="https://www.benzinga.com//node/45117886" target="_blank" rel="noreferrer noopener">consensus estimate of&nbsp;$3.22</a>.</li>
<li>Microsoft says its focus on cloud services and customer-centric solutions could help the company not only survive a recession<a href="https://www.benzinga.com//node/45125965" target="_blank" rel="noopener"> but also</a><a href="https://www.benzinga.com//node/45125965" target="_blank" rel="noreferrer noopener"> grow through it</a>.</li>
<li>Microsoft guided&nbsp;fourth-quarter&nbsp;cloud margins to about&nbsp;67%, with intelligent cloud revenue expected between&nbsp;$28.75 billion&nbsp;and&nbsp;$29.05 billion.</li>
<li>Goldman Sachs analyst Kash Rangan says that despite macroeconomic uncertainty and potential tariff risks, the company is set up to post free cash flow growth of 3% and earnings-per-share growth of 17% in fiscal year 2026, with <a href="https://www.benzinga.com//node/45137383" target="_blank" rel="noreferrer noopener">Azure maintaining a 30% growth rate</a>.</li>
<li>KeyBanc analyst Jackson Ader writes that the quarter highlights a principal risk in not being overweight MSFT right now: We have no visibility into capacity unlocks. Microsoft&#8217;s return on investment math for AI is still difficult to make sense of, and there could be <a href="https://www.benzinga.com//node/45149535" target="_blank" rel="noreferrer noopener">better stocks to play &#8220;offense&#8221; with</a>.</li>
<li>Microsoft-Backed OpenAI&nbsp;has&nbsp;agreed to buy&nbsp;Windsurf&nbsp;for about&nbsp;$3 billion to take on&nbsp;competition&nbsp;in the market for <a href="https://www.benzinga.com//node/45224667" target="_blank" rel="noreferrer noopener">AI-driven coding assistants</a>.</li>
<li>YTD, Microsoft has risen around 3.12%, outperforming the&nbsp;iShares U.S. Technology ETF&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IYW#NYSE">IYW</a>), which lost about 9.93%&nbsp;over the same time frame.</li>
</ul>
Fortive Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FTV#NYSE">FTV</a>): In the fourth quarter of 2024, the investor acquired a stake of 1,900,000 shares <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" target="_blank" rel="noreferrer noopener">in </a>the company.
<ul>
<li>Fortive&nbsp;reported first quarter adjusted EPS&nbsp;of $0.85, which is in line with the consensus and, sales of $1.47 billion <a href="https://www.benzinga.com//node/45130994" target="_blank" rel="noreferrer noopener">missed the consensus of&nbsp;$1.49 billion</a>.</li>
<li>The company projects second quarter adjusted EPS of&nbsp;$0.85-$0.90&nbsp;<a href="https://www.benzinga.com/calendars/guidance" target="_blank" rel="noreferrer noopener">vs. street estimate of $0.98</a>.</li>
<li>The company lowered FY25 adjusted EPS&nbsp;guidance&nbsp;from&nbsp;$4.00-$4.12&nbsp;to&nbsp;$3.80-$4.00&nbsp;vs&nbsp;consensus of $4.02.</li>
<li>Fortive appointed Neill Reynolds as CFO of Ralliant, effective June 2, 2025, and announced the filing of a Form 10 registration statement <a href="https://www.benzinga.com//node/45190836" target="_blank" rel="noreferrer noopener">for the planned spin-off of Ralliant</a>.</li>
<li>Barclays analyst Julian Mitchell maintained an Overweight rating and lowered the price forecast from $85 to $84.</li>
<li>YTD, Fortive declined around 10.91%, underperforming the WisdomTree U.S. AI Enhanced Value Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AIVL#NYSE">AIVL</a>), which lost about 0.04%&nbsp;over the same time frame.</li>
</ul>
Hess Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HES#NYSE">HES</a>): Third Point held 625,000 shares in the company <a href="https://www.sec.gov/Archives/edgar/data/1040273/000108514625001713/xslForm13F_X02/infotable.xml" target="_blank" rel="noopener">as </a>of the fourth quarter of 2024.
<ul>
<li>Hess reported first-quarter adjusted EPS of $1.81, which beat the consensus estimate of $1.61 and sales of $2.94 billion, <a href="https://www.benzinga.com//node/45096392" target="_blank" rel="noreferrer noopener">exceeded the estimated $2.71 billion</a>.</li>
<li>The company projects a total production of 480-490 MBOE per day <a href="https://investors.hess.com/static-files/a2100eac-445b-437c-9224-d0d56a20b5f4" target="_blank" rel="noreferrer noopener">and </a>Exploration and Production Capital and Exploratory Expenditures of $1.27 billion in the second quarter.</li>
<li>YTD, Hess declined around 5.07%, vs. the Invesco S&amp;P 500 Equal Weight Energy ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSPG#NYSE">RSPG</a>), which declined about 10.63%&nbsp;over the same time frame.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/04/45048902/tariffs-bite-dan-loebs-portfolio-thermo-fisher-hit-hard-discover-shines" target="_blank" rel="noreferrer noopener">Tariffs Bite Dan Loeb&#8217;s Portfolio: Thermo Fisher Hit Hard, Discover Shines</a></li>
</ul>
Photo: Shutterstock

Large Cap

AIVL

AMZN

iShares Trust S&P Global Telecommunications Sector Index Fund

iShares Dow Jones US Technology Sector Index Fund

MSFT

ONLN

RSPG

Amazon, Meta, Microsoft Earnings Put Dan Loeb's Portfolio To The Test

Mattel Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) shares are trading higher Tuesday, even after the toymaker announced it would pause its full-year 2025 guidance <a href="https://www.benzinga.com/news/earnings/25/05/45209947/mattel-beats-q1-estimates-pauses-guidance-due-to-tariffs-plans-actions-to-mitigate-cost-impacts">due to tariff uncertainty. </a>
What To Know: The move comes alongside better-than-expected first-quarter results and a series of cost-cutting plans aimed at offsetting future trade-related impacts.
In the first quarter, Mattel reported revenue of $827 million, surpassing analyst expectations of $786 million. The company posted an adjusted loss of three cents per share, narrower than the expected 10-cent loss. Revenue rose 2% year-over-year, with gains in both North American and international markets. Gross margin improved to 49.4%, up from 48% a year earlier.
Despite the solid quarterly performance, Mattel said it is withholding forward guidance as it evaluates the effects of the evolving U.S. tariff landscape. The company said it plans to mitigate potential cost increases through supply chain diversification, product sourcing adjustments, pricing changes, and additional cost-saving measures. It raised its 2025 cost savings target from $60 million to $80 million.
MAT Price Action: Mattel shares were up 2.50% at $16.61 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/05/45231535/stocks-fall-on-trade-concerns-oil-and-gold-rally-whats-driving-markets-tuesday">Stocks Fall On Trade Concerns, Oil And Gold Rally: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Image Via Shutterstock.

Mattel Stock Edges Higher Despite Paused Guidance Over Tariff Concerns: What's Going On?

WIIM

Celanese shares are trading higher after the company reported better-than-expected Q1 financial results.

Upwork Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPWK#NASDAQ">UPWK</a>) shares are trading higher Tuesday following better-than-expected first-quarter earnings and an upward revision to its <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45228179/upwork-delivers-solid-start-to-2025-analyst">full-year profit forecast.</a>
What To Know: The company reported adjusted earnings of 34 cents per share, beating the consensus estimate of 26 cents. Revenue came in at $192.71 million, also ahead of forecasts and slightly higher than the $190.94 million reported in the same quarter last year. 
The number of active clients reached 812,000 and gross services volume per client increased 3% year-over-year, marking the first positive growth in that metric in six quarters.
Upwork also raised its full-year 2025 adjusted earnings per share guidance to a range of $1.14 to $1.18, up from the previous range of $1.05 to $1.10. That new guidance exceeds Wall Street's estimate of $1.07. The company maintained its full-year revenue outlook between $740 million and $760 million, roughly in line with expectations.
UPWKL Price Action: Upwork shares were up 19% at $15.85 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/05/45231535/stocks-fall-on-trade-concerns-oil-and-gold-rally-whats-driving-markets-tuesday">Stocks Fall On Trade Concerns, Oil And Gold Rally: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Image Via Shutterstock.

UPWK

Upwork Stock Surges After Q1 Earnings And Raised FY25 Guidance: What's Going On?

CCCS

CCC Intelligent Solutions Holdings shares are trading lower after the company reported Q1 financial results and issued Q2 sales guidance below estimates. Also, the company cut its FY25 sales guidance with its midpoint below estimates.

Oklo Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OKLO#NYSE">OKLO</a>) shares are trading higher by 8.6% to $27.67 Tuesday afternoon after Axios <a href="https://www.axios.com/pro/energy-policy/2025/05/06/scoop-white-house-seeks-to-hasten-nuclear-deployment">reported</a> that the White House is preparing executive orders aimed at fast-tracking the deployment of nuclear reactors. 
The news sparked investor enthusiasm for advanced nuclear developer Oklo, which specializes in compact reactors designed to deliver power for data centers, defense applications and remote sites.
What To Know: According to Axios, the planned executive actions would leverage the Departments of Defense (DOD) and Energy (DOE) to bypass traditional licensing delays from the Nuclear Regulatory Commission (NRC). 
Citing multiple anonymous sources, Axios <a href="https://www.axios.com/pro/energy-policy/2025/05/06/scoop-white-house-seeks-to-hasten-nuclear-deployment">noted</a> the DOD could play a &#8220;key enabler&#8221; role due to its substantial energy needs and capacity to absorb regulatory risk.
Read Also: <a href="https://www.benzinga.com/news/25/05/45227011/whats-going-on-with-soundhound-ai-soun-stock">What&#8217;s Going On With SoundHound AI Stock?</a>
One source told Axios the move would promote faster reactor deployment by forming a DOD-DOE partnership, avoiding NRC bottlenecks.
What Else: Oklo, which recently went public via a SPAC backed by <a href="https://www.benzinga.com/trading-ideas/movers/25/04/44937524/oklo-stock-falls-as-sam-altman-steps-down-as-board-chair-now-is-the-right-time">former board chairman</a> Sam Altman, has gained attention for its potential role in powering AI infrastructure. 
With rising energy demands from hyperscalers, Oklo's scalable, clean nuclear solutions may increasingly be viewed as a strategic asset. Investors on Tuesday appear to be betting that the White House's nuclear push could significantly benefit Oklo's business.
Read Also: <a href="https://www.benzinga.com/news/25/05/45231053/tempus-ai-tem-stock-lower-ahead-of-q1-earnings-report-notetaker-ai-debut">Tempus AI Stock Lower Ahead Of Q1 Earnings Report, Notetaker AI Debut</a>
<h2 class="wp-block-heading">How To Buy OKLO Stock</h2>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in Oklo&#8217;s case, it is in the Utilities sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
According to data from&nbsp;<a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, OKLO has a 52-week high of $59.14 and a 52-week low of $5.35.

OKLO

Oklo Stock Soars As White House Reportedly Eyes Executive Action To Accelerate Nuclear Deployment

Rivian Automotive Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIVN#NASDAQ">RIVN</a>) and Lucid Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LCID#NASDAQ">LCID</a>) are both set to report earnings after the close on Tuesday. Both carmakers are bleeding cash, but only one <a href="https://www.benzinga.com/topic/electric-vehicle">seems to be gaining traction</a>.
<h2 class="wp-block-heading">Rivian: Building Momentum And Infrastructure</h2>
Wall Street is bracing for Rivian <a href="https://www.benzinga.com/quote/RIVN/earnings">to post a</a> loss of 76 cents per share on $1 billion in revenue, but pre-earnings sentiment is leaning cautiously optimistic.
The Irvine, California-based company just unveiled plans to spend $120 million on a 1.2 million-square-foot supplier park next to its Illinois factory, <a href="https://stocktwits.com/news-articles/markets/equity/rivian-to-build-120-million-dollar-supplier-park-in-illinois/chiI3uORbSb">reported</a> Stocktwits. The strategic move, meant to streamline operations ahead of R2 production in 2026, adds credibility to the EV maker's long-term story. 
Still, the stock dipped 1% in early trading as investors wait to see whether words will turn into numbers.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/05/45205696/rivian-q1-earnings-preview-all-eyes-on-r2-launch-analyst-says-no-catalysts-in-2025">Rivian Q1 Earnings Preview: All Eyes On R2 Launch, Analyst Says &#8216;No Catalysts In 2025&#8217;</a>
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="633" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06135058/Screenshot-2025-05-06-at-11.20.31-PM.png" alt="" class="wp-image-904030" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06135058/Screenshot-2025-05-06-at-11.20.31-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06135058/Screenshot-2025-05-06-at-11.20.31-PM-300x232.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Still, Rivian&#8217;s stock is in the fast lane, trading above its 20, 50 and 200-day simple moving averages (SMAs). Its Moving Average Convergence Divergence (MACD) indicator sits at 0.48, and the Relative Strength Index (RSI) is a comfortable 58.74 &#8211; signaling strong but not overheated momentum. Recent selling pressure can be seen as the stock trades below its eight-day SMA of $13.39.
Shares are up just 1% year to date, but the setup looks bullish overall in terms of earnings, especially with infrastructure expansion backing the narrative.
<h2 class="wp-block-heading">Lucid: Low Power Mode?</h2>
Lucid is <a href="https://www.benzinga.com/quote/LCID/earnings">expected to report</a> a 23-cent per-share loss on $250 million in revenue. But unlike Rivian, pre-earnings sentiment is weaker.
Lucid&#8217;s recent <a href="https://ir.lucidmotors.com/news-releases/news-release-details/lucid-and-saudi-arabias-kaust-announce-strategic-partnership#:~:text=IR%20Menu-,Lucid%20and%20Saudi%20Arabia's%20KAUST%20Announce%20Strategic%20Partnership%20to%20Advance,Advanced%20Driver%20Assist%20System%20Capabilities&amp;text=KING%20ABDULLAH%20ECONOMIC%20CITY%2C%20Saudi,%2F%20%2D%2D%20Lucid%20Group%2C%20Inc.">announcement </a>of a high-tech partnership with Saudi Arabia's KAUST to develop autonomous driving components and AI hardware was quickly overshadowed by geopolitical jitters. As the Saudi Public Investment Fund remains Lucid's largest backer, rising tariff risks under the Trump administration are spooking investors.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506"><img loading="lazy" decoding="async" width="633" height="489" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06135607/Screenshot-2025-05-06-at-11.20.43-PM.png" alt="" class="wp-image-904043" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06135607/Screenshot-2025-05-06-at-11.20.43-PM.png 633w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/06135607/Screenshot-2025-05-06-at-11.20.43-PM-300x232.png 300w" sizes="(max-width: 633px) 100vw, 633px" /></a></figure>
<a href="https://www.benzinga.com/pro/register?utm_adType=bzprocontent&amp;utm_campaign=14daytrial&amp;utm_ad=0506" target="_blank" rel="noreferrer noopener">Chart created using Benzinga Pro</a>
Technically, the setup is shaky. Newark, California-based Lucid is trading below its five, 20 and 50-day moving averages — classic bearish territory. RSI is stuck at 42.13, and the MACD is 0.00, lacking any direction and conviction.
Lucid stock is down nearly 24% so far in 2025. Investors may be more interested in clarity on Gravity SUV timelines and tech licensing than Tuesday&#8217;s revenue number.
With both Rivian and Lucid earnings on deck, signals suggest only one EV stock has the green light.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45205881/lucid-q1-earnings-preview-lower-priced-gravity-tariff-concerns-market-share-gains-from-tesla-top-items-to-watch">Lucid Q1 Earnings Preview: Lower-Priced Vehicles, Tariff Concerns, Market Share Gains From Tesla, Top Items To Watch</a></li>
</ul>
Image: Shutterstock

Technicals

Previews

Tech

LCID

RIVN

TSLA

Rivian Vs. Lucid: One Of These Tesla Rivals Is Stuck In Neutral Ahead Of Q1 Earnings

The U.S. Food and Drug Administration (FDA) announced its intent to expand the use of unannounced inspections at foreign manufacturing facilities that produce foods, essential medicines, and other medical products intended for <a target="_blank" href="https://www.benzinga.com/general/health-care" rel="noreferrer noopener">American consumers and patients</a>.
This change builds upon the agency&#8217;s Office of Inspection and Investigations&#8217; Foreign Unannounced Inspection Pilot program in India and China and aims to ensure that foreign companies will receive the same level of regulatory oversight and scrutiny as domestic companies.&nbsp;
&#8220;For too long, foreign companies have enjoyed a double standard—given advanced notice before facility inspections, while American manufacturers are held to rigorous standards with no such warning,&#8221; said FDA Commissioner Martin Makary. &nbsp;
On Tuesday, the FDA <a target="_blank" href="https://www.fda.gov/news-events/press-announcements/fda-announces-expanded-use-unannounced-inspections-foreign-manufacturing-facilities?utm_medium=email&amp;utm_source=govdelivery" rel="noreferrer noopener">said</a> it plans to review and improve its foreign inspection program to ensure it meets the highest standards for oversight. Part of this effort includes making it clear that FDA inspectors should not accept travel-related perks like hotel stays or transportation from the companies they inspect.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/05/45225204/iqvia-beats-q1-earnings-expectations-despite-sector-uncertainty-company-navigating-market-conditions-effectively-says-ceo" rel="noreferrer noopener">IQVIA Beats Q1 Earnings Expectations Despite Sector Uncertainty, Company Navigating Market Conditions &#8216;Effectively&#8217; Says CEO</a>
The FDA conducts about 12,000 inspections annually in the U.S. and 3,000 in other countries. While U.S. companies often get surprise inspections, foreign companies usually receive advanced notice, giving them time to prepare and potentially hide problems.
Still, foreign inspections often reveal serious issues, more than twice as often as domestic ones.
In the U.S., inspections are usually unannounced unless specific programs require advance notice to ensure staff and records are available.
Even then, companies can&#8217;t pick the date or time. The FDA says foreign companies shouldn&#8217;t have that option either.
By shifting to more surprise inspections abroad, the FDA aims to better protect American consumers by catching dishonest practices, like falsifying records or hiding violations, before they cause harm.
The agency can take action against any company that tries to delay, block, or refuse an unannounced inspection.
The update follows President&nbsp;Donald Trump&#8217;s signed executive order on Monday to promote prescription drug manufacturing in the U.S., streamlining the path for companies to build new production sites as potential tariffs on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">imported medicines loom</a>.
The order directs the FDA to reduce the amount of time it takes to approve manufacturing plants in the U.S. by eliminating unnecessary requirements, streamlining reviews, and working with domestic drugmakers to &#8220;provide early support before facilities come online,&#8221; <a target="_blank" href="https://www.whitehouse.gov/fact-sheets/2025/05/fact-sheet-president-donald-j-trump-announces-actions-to-reduce-regulatory-barriers-to-domestic-pharmaceutical-manufacturing/" rel="noreferrer noopener">according</a> to&nbsp;a White House fact sheet.
It also directs the agency to raise inspection fees for foreign manufacturing plants, improve the enforcement of active-ingredient source reporting by overseas producers, and consider publicly listing facilities that don&#8217;t comply.
The White House <a target="_blank" href="https://www.whitehouse.gov/presidential-actions/2025/05/regulatory-relief-to-promote-domestic-production-of-critical-medicines/" rel="noreferrer noopener">estimates</a> that it can currently take five to ten years to build new pharmaceutical manufacturing capacity, which it calls &#8220;unacceptable from a national-security standpoint.&#8221;
<a target="_blank" href="https://www.benzinga.com/markets/25/02/43906811/trump-reportedly-warns-big-pharma-move-manufacturing-to-us-or-face-tariffs" rel="noreferrer noopener">Amid tariff uncertainty</a>, many companies have disclosed a wave of investments in recent months to boost production in the U.S.
<ul>
<li>Eli Lilly And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) doubled <a href="https://www.benzinga.com/general/biotech/25/02/43982604/eli-lilly-doubles-capital-spending-on-us-drug-manufacturing-with-50-billion-target" target="_blank" rel="noreferrer noopener">domestic medicine production</a>.</li>
<li>Thermo Fisher Scientific Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TMO#NYSE">TMO</a>) announced it would invest an additional $2 billion in the U.S. over <a href="https://www.benzinga.com/general/health-care/25/04/44995428/thermo-fisher-doubles-down-on-us-manufacturing-in-2b-expansion-plan" target="_blank" rel="noreferrer noopener">the next four years</a>.</li>
<li>Medtech firm Becton, Dickinson, and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BDX#NYSE">BDX</a>) also announced its intention to invest $2.5 billion in U.S. manufacturing capacity <a href="https://www.benzinga.com/general/health-care/25/05/45140102/potential-tariff-bites-into-becton-dickinson-2025-profit-outlook-company-will-invest-2-5-billion-to-boost-us-manufacturing" target="_blank" rel="noreferrer noopener">over the next 5 years</a>.</li>
<li>Pfizer Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) did not highlight investments in new manufacturing plants; it noted that they already have significant capacity and flexibility to manufacture <a href="https://www.benzinga.com/general/biotech/25/04/45118145/pfizer-ceo-albert-bourla-emphasizes-national-security-in-us-drug-manufacturing" target="_blank" rel="noreferrer noopener">their products in the U.S</a>.</li>
<li>Regeneron Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) seeks to nearly double its manufacturing capacity through a new agreement with <a href="https://www.benzinga.com/general/biotech/25/04/44931246/regeneron-partners-with-japan-based-fujifilm-to-bolster-us-manufacturing-capacity-via-3-billion-deal" target="_blank" rel="noreferrer noopener">FUJIFILM Diosynth Biotechnologies</a>.</li>
<li>Novartis AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>) unveiled a sweeping $23 billion investment plan to expand its manufacturing and research infrastructure in the U.S. <a href="https://www.benzinga.com/general/biotech/25/04/44761201/novartis-commits-23-billion-to-expand-us-manufacturing-over-five-years-despite-tariffs-uncertaint" target="_blank" rel="noreferrer noopener">over the next five years</a>.</li>
<li>Johnson &amp; Johnson (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JNJ#NYSE">JNJ</a>) announced its plans to invest more than <a href="https://www.benzinga.com/markets/equities/25/03/44433978/johnson-johnson-to-invest-55-billion-in-us-to-boost-manufacturing-drug-discovery" target="_blank" rel="noreferrer noopener">$55 billion in the U.S. over the next four years</a>.</li>
<li>Roche Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>) announced that it will invest $50 billion in the U.S. over <a href="https://www.benzinga.com/topic/pharmaceuticals" target="_blank" rel="noreferrer noopener">the next five years.</a></li>
<li>Most recently, Bristol-Myers Squibb &amp; Co.&#8217;s (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) Christopher Boerner, chair and chief executive officer, <a href="https://www.statnews.com/2025/05/05/bristol-myers-squibb-pharmaceutical-policy-us-trump-administration-innovation-tariffs/" target="_blank" rel="noreferrer noopener">shared</a> plans to invest $40 billion in U.S. R&amp;D, technology, and manufacturing over the next five years in an op-ed published by Stat this week.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/25/05/45195137/footwear-titans-nike-adidas-call-tariffs-an-existential-threat-appeal-to-trump-for-relief-this-is-an-emergency" target="_blank" rel="noreferrer noopener">Footwear Titans Nike, Adidas Call Tariffs An &#8216;Existential Threat&#8217;, Appeal To Trump For Relief: &#8216;This Is An Emergency&#8217;</a></li>
</ul>
Photo by Tada Images via Shutterstock

Biotech

Government

Regulations

Health Care

REGN

RHHBY

FDA Expands Surprise Inspections At Foreign Drug And Food Facilities, Targets Double Standards In Overseas Manufacturing Oversight

Eli Lilly and Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>) shares are trading lower Tuesday. The stock appears to be moving in reaction to an executive order from the Trump administration aimed at <a href="https://www.benzinga.com/government/regulations/25/05/45215281/trump-orders-fda-to-fast-track-us-drug-production-as-tariff-threat-looms-on-imported-medicines-cites-national-security-concerns">boosting domestic drug manufacturing</a>.
What To Know: President Donald Trump signed a new executive order late Monday that aims to reshape the pharmaceutical supply chain by incentivizing drug manufacturers in the U.S., according to <a href="https://www.cnbc.com/2025/05/05/trump-order-us-drug-manufacturing.html">CNBC.</a>
The order calls on federal agencies to speed up approval for U.S.-based manufacturing facilities, increase inspection fees on overseas drugmakers and streamline permitting through a coordinated, centralized process. 
The executive order directs the FDA to increase fees for foreign manufacturing plants and proposes publicizing facilities that fail to meet compliance standards. A key provision calls for &#8220;surprise&#8221; inspections abroad, ending the practice of giving advance notice to international sites, which U.S. plants are already subject to.
The policy shift comes as pharmaceutical imports into the U.S. remain high with $203 billion in imports in 2023 alone. Nearly 75% of the imported pharmaceutical products in 2023 came from Europe, mainly Ireland, Germany and Switzerland.
Although Eli Lilly manufactures a lot of its products in the U.S., the company has significant operations and investments in both Ireland and Germany. Eli Lilly also imports a lot of its pharmaceutical ingredients, however, the company <a href="https://www.benzinga.com/content/44189496/eli-lilly-pours-27b-into-u-s-growth-what-it-means-for-investors">announced plans</a> in February to invest $27 billion in U.S. manufacturing, with most plants focused on pharmaceutical ingredient manufacturing.
The new executive order aims to reduce this dependency by encouraging U.S.-based production, which government officials argue is essential for national security and supply chain resilience.
Drugmakers such as Eli Lilly could face cost pressures from the realignment. The Trump administration is also preparing to <a href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market">announce tariffs</a> on imported pharmaceuticals, adding another layer of uncertainty for companies with global supply chains. Several pharmaceutical stocks appear to be moving lower in response to the announcement and the potential implications for operating costs and regulatory compliance.
LLY Price Action: Eli Lilly shares were down 6.06% at $771.69 at the time of publication Tuesday, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Read next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/05/45231535/stocks-fall-on-trade-concerns-oil-and-gold-rally-whats-driving-markets-tuesday">Stocks Fall On Trade Concerns, Oil And Gold Rally: What&#8217;s Driving Markets Tuesday?</a></li>
</ul>
Image via Shutterstock.

Global

Eli Lilly Stock Is Sliding Tuesday: What's Going On?

Billionaire hedge fund manager Paul Tudor Jones believes the U.S. economy is either in or near recession. He also expects stocks to fall to new lows this year, but he has made similar predictions multiple times in recent years <a href="https://www.benzinga.com/trading-ideas/short-ideas/22/10/29205954/paul-tudor-jones-correctly-predicted-the-1987-stock-market-crash-heres-what-the-billion">and been wrong.</a>
What To Know: Jones predicted Tuesday morning on CNBC&#8217;s &#8220;Squawk Box&#8221; that a recession is nearing if the economy isn&#8217;t already in the middle of one.
&#8220;I don&#8217;t know whether it started now or it started two months ago &#8230; But I&#8217;m assuming we are going to go into one,&#8221; Jones said on the show.
He also predicted that President Donald Trump will ease tariffs on China to around 40% or 50%, from the current average of around 125% for most products. 
&#8220;I&#8217;m sure he&#8217;ll dial it back to 50 [percent]. I think that&#8217;s kind of in the market right now,&#8221; he said. 
He indicated that an easing of tariffs on China is already priced in and won&#8217;t save the markets from heading to new lows for the year. He believes the damage is already done, suggesting that one could assume 2% to 3% lower growth. 
He said that when combined with the Federal Reserve, which is <a href="https://www.benzinga.com/25/03/44403637/fed-keeps-interest-rates-unchanged-forecasts-hotter-inflation-lower-growth-ahead" target="_blank" rel="noopener">standing firm on rates</a>, it&#8217;s a recipe for new lows for broader markets.
&#8220;You're probably gonna go to new lows. And then when we&#8217;re at new lows, the hard day will start to follow and it&#8217;ll probably create the Fed to move, create Trump to move, and we&#8217;ll get some kind of reality,&#8221; Jones said. 
Check This Out: <a href="https://www.benzinga.com/government/regulations/25/05/45227387/bessent-signals-imminent-trade-deals-dismisses-recession-fears-as-stocks-rebound">Bessent Signals Imminent Trade Deals, Dismisses Recession Fears As Stocks Rebound</a>
Why It Matters: Jones is well known for predicting the stock market crash of 1987, known&nbsp;as &#8220;Black Monday.&#8221; He&#8217;s also called for recession and a stock market crash multiple times in recent years and been wrong. 
With markets trending down in 2022, he <a href="https://www.benzinga.com/trading-ideas/short-ideas/22/10/29205954/paul-tudor-jones-correctly-predicted-the-1987-stock-market-crash-heres-what-the-billion">appeared on CNBC</a> and predicted that a recession was coming.
&#8220;[Jerome] Powell&#8217;s already talked about pain. I take that as a metaphor for recession. And if we go into recession, that has really negative consequences for a variety of assets,&#8221; Jones said on Oct. 10, 2022.
As it turned out, October marked the bottom for stocks in 2022 and the S&amp;P 500 ended up racing higher throughout 2023, offering approximately 24% gains for investors who held onto positions. Jones actually used almost<a href="https://www.benzinga.com/trading-ideas/short-ideas/22/10/29205954/paul-tudor-jones-correctly-predicted-the-1987-stock-market-crash-heres-what-the-billion"> identical language</a> in 2022 as he did on Tuesday, noting at the time that he was &#8220;assuming we are going to go into&#8221; a recession, if we weren&#8217;t already in one.
Jones also came on CNBC in October 2023 and predicted that stocks were going to crash because of the <a href="https://www.benzinga.com/markets/equities/23/10/35167330/paul-tudor-jones-warns-stocks-could-plunge-with-threat-of-nuclear-war-led-by-sociopaths-in-china">threat of nuclear war</a>. He added that we were probably headed into a recession in early 2024. He was wrong about that as well.
&#8220;It's a really challenging time to want to be an equity investor and in U.S. stocks right now,&#8221; Jones said in October 2023. 
October 2023 also marked another low for stocks, with the S&amp;P 500 rallying into year&#8217;s end and then returning approximately 23% in 2024.
The SPDR S&amp;P 500 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which tracks the S&amp;P 500, was off the lows for Tuesday&#8217;s session, down 0.56% at $560.32 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://in.benzinga.com/tech/25/05/45229107/paul-tudor-jones-warns-ai-could-kill-50-of-humanity-without-proper-oversight-were-creating-something-thats-really-dangerous">Paul Tudor Jones Warns AI Could &#8216;Kill 50% Of Humanity&#8217; Without Proper Oversight: &#8216;We&#8217;re Creating Something That&#8217;s Really Dangerous&#8217;</a></li>
</ul>
Photo: <a href="https://www.shutterstock.com/g/KatherleenSee">zignal_88</a>/Shutterstock.

Hedge Funds

Paul Tudor Jones Predicts Recession, New Market Lows, But His Past Bearish Calls In 2022, 2023 Missed Big Rallies

Fiserv, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FI#NYSE">FI</a>), a leading global provider of payments and financial services technology solutions, today announced that Michael P. Lyons has been appointed Chief Executive Officer of Fiserv. Lyons assumed the position upon the confirmation of Frank Bisignano, Fiserv's prior CEO, as Commissioner of the Social Security Administration. Lyons also joins the Fiserv Board of Directors.

Management

Fiserv Appoints Michael Lyons As CEO

WK Kellogg Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLG#NYSE">KLG</a>) reported <a target="_blank" href="https://www.benzinga.com/pressreleases/25/05/n45218611/wk-kellogg-co-announces-first-quarter-2025-results-and-updates-2025-outlook" rel="noreferrer noopener">first-quarter results</a> on Tuesday.
The company <a target="_blank" href="https://s203.q4cdn.com/450659508/files/doc_financials/2025/q1/KLG-2025-Q1-Exhibit-99-1.pdf" rel="noreferrer noopener">clocked</a> earnings per share of 20 cents, missing the street view of 34 cents. Quarterly sales of $663 million missed the analyst consensus estimate of $679.49 million.
Quarterly reported net sales declined 6.2% year-over-year, while organic net sales were down 5.6% from the prior year. The drop in organic net sales was driven by reduced retailer inventory tied to Easter holiday timing, the comparison against a major prior-year promotion, and softer-than-expected consumption trends.
Also Read: <a target="_blank" href="https://www.benzinga.com/economics/macro-economic-events/25/05/45220645/us-trade-deficit-soars-to-record-140b-as-imports-rocket-ahead-of-trumps-tariffs" rel="noreferrer noopener">US Trade Deficit Soars To Record $140B As Imports Rocket Ahead Of Trump&#8217;s Tariffs</a>
Adjusted EBITDA in the quarter under review was $72 million, down 4% year over year. This decrease was driven by lower sales volume. Adjusted EBITDA margin expanded to 10.8% from 10.6% in the year-ago period.
In the first quarter, price/mix rose 3.0% while volume declined 8.6%.
Chairman and CEO Gary Pilnick said the company remains on track to achieve a margin improvement of around 500 basis points by the end of 2026.
&#8220;In the first quarter, we saw consumers continue to focus on health and nutrition, which we view as a positive development for the category,&#8221; Pilnick added.
Outlook: The company said 2025 organic net sales are now projected to fall approximately between (2.0)% and (3.0)%, compared to the prior guidance of a (1.0)% decline.
2025 adjusted EBITDA growth is now projected to be flat to down (2.0)%, compared to the prior guidance of 4% to 6% growth.
The 2025 financial outlook includes a modest impact from tariffs, mainly tied to raw materials sourced outside North America.
It assumes most production remains exempt from tariffs on trade with Canada and Mexico.
However, the company said, there is no guarantee that these exemptions will continue or that future tariffs will not further affect the business and financial results.
Price Action: KLG shares are trading higher by 2.25% to $17.75 at last check on Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/25/05/45205432/opec-just-created-the-income-trade-of-the-decade" target="_blank" rel="noreferrer noopener">OPEC Just Created The Income Trade Of The Decade</a></li>
</ul>

Earnings

Guidance

WK Kellogg Q1 Profit Slumps, Flags Modest Tariff Impact From Raw Material Sourcing

MISTRAS Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MG#NYSE">MG</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that MISTRAS Group will report an earnings per share (EPS) of $0.12.
MISTRAS Group bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Performance in Previous Earnings</h3>
In the previous earnings release, the company beat EPS by $0.11, leading to a 12.19% increase in the share price the following trading session.
Here's a look at MISTRAS Group's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.13</td>
<td>0.27</td>
<td>0.13</td>
<td>0.04</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.24</td>
<td>0.20</td>
<td>0.21</td>
<td>0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>12.0%</td>
<td>-24.0%</td>
<td>1.0%</td>
<td>1.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746558260_0.png" alt="eps graph" />
<h3>Market Performance of MISTRAS Group's Stock</h3>
Shares of MISTRAS Group were trading at $9.46 as of May 05. Over the last 52-week period, shares are up 5.73%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/MG/earnings">To track all earnings releases for MISTRAS Group visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Outlook For MISTRAS Group

CPI Card (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMTS#NASDAQ">PMTS</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement.
Analysts estimate that CPI Card will report an earnings per share (EPS) of $0.69. 
Investors in CPI Card are eagerly awaiting the company's announcement, hoping for news of surpassing estimates and positive guidance for the next quarter.
It's worth noting for new investors that stock prices can be heavily influenced by future projections rather than just past performance.
<h3>Earnings Track Record</h3>
The company's EPS beat by $0.02 in the last quarter, leading to a 2.4% drop in the share price on the following day.
Here's a look at CPI Card's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.55</td>
<td>0.51</td>
<td>0.58</td>
<td>0.41</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.57</td>
<td>0.66</td>
<td>0.51</td>
<td>0.46</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>11.0%</td>
<td>-18.0%</td>
<td>3.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746558250_0.png" alt="eps graph" />
<h3>Tracking CPI Card's Stock Performance</h3>
Shares of CPI Card were trading at $26.12 as of May 05. Over the last 52-week period, shares are up 21.81%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release. 
<a href="https://www.benzinga.com/quote/PMTS/earnings">To track all earnings releases for CPI Card visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PMTS

Preview: CPI Card's Earnings

The One Group Hospitality (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/STKS#NASDAQ">STKS</a>) is gearing up to announce its quarterly earnings on Wednesday, 2025-05-07. Here's a quick overview of what investors should know before the release.
Analysts are estimating that The One Group Hospitality will report an earnings per share (EPS) of $-0.14.
The announcement from The One Group Hospitality is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Performance in Previous Earnings</h3>
The company's EPS missed by $0.06 in the last quarter, leading to a 11.67% drop in the share price on the following day.
Here's a look at The One Group Hospitality's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.03</td>
<td>0.01</td>
<td>0.06</td>
<td>0.03</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.03</td>
<td>-0.30</td>
<td>0.08</td>
<td>-0.02</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-12.0%</td>
<td>-19.0%</td>
<td>-11.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746558229_0.png" alt="eps graph" />
<h3>Market Performance of The One Group Hospitality's Stock</h3>
Shares of The One Group Hospitality were trading at $3.01 as of May 05. Over the last 52-week period, shares are down 33.91%. Given that these returns are generally negative, long-term shareholders are likely bearish going into this earnings release. 
<h3>Analysts' Take on The One Group Hospitality</h3>
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on The One Group Hospitality.
Analysts have given The One Group Hospitality a total of 2 ratings, with the consensus rating being Neutral. The average one-year price target is $4.25, indicating a potential 41.2% upside.
<h3>Understanding Analyst Ratings Among Peers</h3>
The analysis below examines the analyst ratings and average 1-year price targets of GEN Restaurant Gr, Potbelly and El Pollo Loco Holdings, three significant industry players, providing valuable insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for GEN Restaurant Gr, with an average 1-year price target of $11.0, suggesting a potential 265.45% upside.</li>
<li>Analysts currently favor an Buy trajectory for Potbelly, with an average 1-year price target of $16.0, suggesting a potential 431.56% upside.</li>
<li>Analysts currently favor an Buy trajectory for El Pollo Loco Holdings, with an average 1-year price target of $18.0, suggesting a potential 498.01% upside.</li>
</ul>
<h3>Peer Metrics Summary</h3>
The peer analysis summary presents essential metrics for GEN Restaurant Gr, Potbelly and El Pollo Loco Holdings, unveiling their respective standings within the industry and providing valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>One Group Hospitality</td>
<td>Neutral</td>
<td>146.71%</td>
<td>$44.22M</td>
<td>-10.98%</td>
</tr>
<tr>
<td>GEN Restaurant Gr</td>
<td>Buy</td>
<td>21.16%</td>
<td>$5.08M</td>
<td>-1.66%</td>
</tr>
<tr>
<td>Potbelly</td>
<td>Buy</td>
<td>-7.25%</td>
<td>$38.97M</td>
<td>8.29%</td>
</tr>
<tr>
<td>El Pollo Loco Holdings</td>
<td>Buy</td>
<td>2.60%</td>
<td>$24.14M</td>
<td>2.08%</td>
</tr>
</tbody>
</table>

Key Takeaway:
The One Group Hospitality ranks at the top for Revenue Growth among its peers. It is at the bottom for Gross Profit and Return on Equity.
<h3>Discovering The One Group Hospitality: A Closer Look</h3>
The One Group Hospitality Inc is a restaurant company that develops, owns and operates, manages and licenses upscale and polished casual, high-energy restaurants and lounges and provides turn-key food and beverage (F&amp;B) services for hospitality venues, including hotels, casinos, and other high-end locations internationally. The company operates through four segments: STK, Benihana and Grill Concepts. The company generates the vast majority of its revenue from the domestic market.
<h3>Breaking Down The One Group Hospitality's Financial Performance</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: The One Group Hospitality displayed positive results in 3 months. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 146.71%. This indicates a notable increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company excelled with a growth rate higher than the average among peers.
Net Margin: The One Group Hospitality's net margin excels beyond industry benchmarks, reaching -2.44%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The One Group Hospitality's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -10.98%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): The One Group Hospitality's ROA stands out, surpassing industry averages. With an impressive ROA of -0.57%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: The One Group Hospitality's debt-to-equity ratio stands notably higher than the industry average, reaching 13.59. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.
<a href="https://www.benzinga.com/quote/STKS/earnings">To track all earnings releases for The One Group Hospitality visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

STKS

The One Group Hospitality's Earnings Outlook

Vanda Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VNDA#NASDAQ">VNDA</a>) is preparing to release its quarterly earnings on Wednesday, 2025-05-07. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Vanda Pharma to report an earnings per share (EPS) of $-0.02.
Vanda Pharma bulls will hope to hear the company announce they've not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the next quarter.
New investors should note that it is sometimes not an earnings beat or miss that most affects the price of a stock, but the guidance (or forecast).
<h3>Earnings Track Record</h3>
Last quarter the company beat EPS by $0.06, which was followed by a 5.96% drop in the share price the next day.
Here's a look at Vanda Pharma's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.14</td>
<td>-0.16</td>
<td>-0.21</td>
<td>0.05</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.08</td>
<td>-0.09</td>
<td>-0.08</td>
<td>-0.07</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-6.0%</td>
<td>3.0%</td>
<td>-3.0%</td>
<td>-7.000000000000001%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746558207_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Vanda Pharma were trading at $4.59 as of May 05. Over the last 52-week period, shares are down 18.75%. Given that these returns are generally negative, long-term shareholders are likely a little upset going into this earnings release. 
<h3>Analyst Observations about Vanda Pharma</h3>
For investors, staying informed about market sentiments and expectations in the industry is paramount. This analysis provides an exploration of the latest insights on Vanda Pharma.
The consensus rating for Vanda Pharma is Buy, based on 2 analyst ratings. With an average one-year price target of $20.0, there's a potential 335.73% upside.
<h3>Peer Ratings Overview</h3>
The following analysis focuses on the analyst ratings and average 1-year price targets of Emergent BioSolutions, 2seventy bio and Lexicon Pharmaceuticals, three prominent industry players, providing insights into their relative performance expectations and market positioning.
<ul>
<li>Analysts currently favor an Buy trajectory for Emergent BioSolutions, with an average 1-year price target of $15.0, suggesting a potential 226.8% upside.</li>
<li>Analysts currently favor an Neutral trajectory for 2seventy bio, with an average 1-year price target of $5.0, suggesting a potential 8.93% upside.</li>
<li>Analysts currently favor an Buy trajectory for Lexicon Pharmaceuticals, with an average 1-year price target of $3.8, suggesting a potential 17.21% downside.</li>
</ul>
<h3>Comprehensive Peer Analysis Summary</h3>
Within the peer analysis summary, vital metrics for Emergent BioSolutions, 2seventy bio and Lexicon Pharmaceuticals are presented, shedding light on their respective standings within the industry and offering valuable insights into their market positions and comparative performance.

<table>
<thead>
<tr>
<th>Company</th>
<th>Consensus</th>
<th>Revenue Growth</th>
<th>Gross Profit</th>
<th>Return on Equity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vanda Pharmaceuticals</td>
<td>Buy</td>
<td>17.48%</td>
<td>$50.59M</td>
<td>-0.91%</td>
</tr>
<tr>
<td>Emergent BioSolutions</td>
<td>Buy</td>
<td>-29.86%</td>
<td>$71.30M</td>
<td>-6.32%</td>
</tr>
<tr>
<td>2seventy bio</td>
<td>Neutral</td>
<td>-72.61%</td>
<td>$-5.92M</td>
<td>-8.89%</td>
</tr>
<tr>
<td>Lexicon Pharmaceuticals</td>
<td>Buy</td>
<td>3682.62%</td>
<td>$26.21M</td>
<td>-20.81%</td>
</tr>
</tbody>
</table>

Key Takeaway:
Vanda Pharma ranks highest in Revenue Growth among its peers. It also has the highest Gross Profit margin. However, it has the lowest Return on Equity.
<h3>Unveiling the Story Behind Vanda Pharma</h3>
Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) &amp; nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.
<h3>Key Indicators: Vanda Pharma's Financial Health</h3>
Market Capitalization: Positioned above industry average, the company's market capitalization underscores its superiority in size, indicative of a strong market presence.
Revenue Growth: Vanda Pharma's revenue growth over a period of 3 months has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 17.48%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Vanda Pharma's net margin is impressive, surpassing industry averages. With a net margin of -9.24%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): Vanda Pharma's ROE excels beyond industry benchmarks, reaching -0.91%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of -0.75%, the company showcases effective utilization of assets.
Debt Management: Vanda Pharma's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.02.
<a href="https://www.benzinga.com/quote/VNDA/earnings">To track all earnings releases for Vanda Pharma visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

VNDA

A Glimpse of Vanda Pharma's Earnings Potential

Smith Micro Software (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMSI#NASDAQ">SMSI</a>) is set to give its latest quarterly earnings report on Wednesday, 2025-05-07. Here's what investors need to know before the announcement.
Analysts estimate that Smith Micro Software will report an earnings per share (EPS) of $-0.11. 
The announcement from Smith Micro Software is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Overview of Past Earnings</h3>
The company's EPS missed by $0.00 in the last quarter, leading to a 34.07% drop in the share price on the following day.
Here's a look at Smith Micro Software's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.11</td>
<td>-0.31</td>
<td>-0.35</td>
<td>-0.40</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.11</td>
<td>-0.30</td>
<td>-0.38</td>
<td>-0.45</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-34.0%</td>
<td>-4.0%</td>
<td>-20.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746558196_0.png" alt="eps graph" />
<h3>Stock Performance</h3>
Shares of Smith Micro Software were trading at $1.03 as of May 05. Over the last 52-week period, shares are down 62.19%. Given that these returns are generally negative, long-term shareholders are likely unhappy going into this earnings release. 
<a href="https://www.benzinga.com/quote/SMSI/earnings">To track all earnings releases for Smith Micro Software visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments

HOOKIPA Pharma

Actualités

Dernières nouvelles pour HOOKIPA Pharma (NASDAQ:HOOK) Stock

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL